ZEJULA Drug Patent Profile

When do Zejula patents expire, and when can generic versions of Zejula launch?

Zejula is a drug marketed by Glaxosmithkline and is included in two NDAs. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and eighty-five patent family members in fifty-five countries.

The generic ingredient in ZEJULA is niraparib tosylate. One supplier is listed for this compound. Additional details are available on the niraparib tosylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Zejula

Zejula was eligible for patent challenges on March 27, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 27, 2038. This may change due to patent challenges or generic licensing.

There have been ten patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ZEJULA

International Patents:	285
US Patents:	8
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	61
Drug Prices:	Drug price information for ZEJULA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZEJULA
What excipients (inactive ingredients) are in ZEJULA?	ZEJULA excipients list
DailyMed Link:	ZEJULA at DailyMed

See drug prices for ZEJULA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZEJULA

NDA:

208447

Dosage:

CAPSULE;ORAL

NDA:

214876

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZEJULA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Korean Cancer Study Group	PHASE2
Korea University Anam Hospital	PHASE2
Takeda	PHASE2

See all ZEJULA clinical trials

Pharmacology for ZEJULA

Drug Class	Poly(ADP-Ribose) Polymerase Inhibitor
Mechanism of Action	Poly(ADP-Ribose) Polymerase Inhibitors

Paragraph IV (Patent) Challenges for ZEJULA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZEJULA	Tablets	niraparib tosylate	100 mg, 200 mg and 300 mg	214876	1	2025-06-17

US Patents and Regulatory Information for ZEJULA

ZEJULA is protected by nine US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	ZEJULA	niraparib tosylate	TABLET;ORAL	214876-003	Apr 26, 2023		RX	Yes	Yes			Y
Glaxosmithkline	ZEJULA	niraparib tosylate	TABLET;ORAL	214876-002	Apr 26, 2023		RX	Yes	No				Y
Glaxosmithkline	ZEJULA	niraparib tosylate	TABLET;ORAL	214876-003	Apr 26, 2023		RX	Yes	Yes
Glaxosmithkline	ZEJULA	niraparib tosylate	CAPSULE;ORAL	208447-001	Mar 27, 2017		DISCN	Yes	No
Glaxosmithkline	ZEJULA	niraparib tosylate	TABLET;ORAL	214876-001	Apr 26, 2023		RX	Yes	No			Y
Glaxosmithkline	ZEJULA	niraparib tosylate	CAPSULE;ORAL	208447-001	Mar 27, 2017		DISCN	Yes	No				Y

International Patents for ZEJULA

When does loss-of-exclusivity occur for ZEJULA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Eurasian Patent Organization

European Patent Office

Israel

Japan

Malaysia

Mexico

Morocco

Philippines

Singapore

South Korea

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZEJULA around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2495035	ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ 2-{4-[(3S)-ПИПЕРИДИН-3-ИЛ]ФЕНИЛ}-2Н-ИНДАЗОЛ-7-КАРБОКСАМИДА (PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3-YL]PHENYL}-2H-INDAZOLE-7-CARBOXAMIDE)
Israel	273282	פורמולציות של ניראפריב (Niraparib formulations)
Brazil	PI0408284	derivados de ftalazinona
European Patent Office	1660095	COMPOSES THERAPEUTIQUES (TRICYCLIC PARP INHIBITORS)
Chile	2008000046
Canada	2533423	UTILISATION D'ARNI INHIBITEUR DE L'ACTIVITE PARP POUR LA FABRICATION D'UN MEDICAMENT POUR LE TRAITEMENT DU CANCER (USE OF RNAI INHIBITING PARP ACTIVTIY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER)

Supplementary Protection Certificates for ZEJULA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3490560	PA2025528	Lithuania		PRODUCT NAME: NIRAPARIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, YPAC NIRAPARIBO TOZILATAS, YPAC NIRAPARIBO TOZILATO MONOHIDRATAS, PASIRINKTINAI DERINYJE SU ABIRATERONU, YPAC ABIRATERONO ACETATU; REGISTRATION NO/DATE: EU/1/23/1722 20230419
1633724	2015/016	Ireland		PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
2109608	C201830023	Spain		PRODUCT NAME: NIRAPARIB; NATIONAL AUTHORISATION NUMBER: EU/1/17/1235; DATE OF AUTHORISATION: 20171116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1235; DATE OF FIRST AUTHORISATION IN EEA: 20171116
2240466	300938	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE
2240466	SPC/GB18/018	United Kingdom		PRODUCT NAME: NIRAPARIB TOSYLATE OR A HYDRATE THEREOF, ESPECIALLY THE TOSYLATE MONOHYDRATE; REGISTERED: UK EU/1/17/1235 20171120; UK PLGB 19494/0294 20171120
1633724	C 2015 011	Romania		PRODUCT NAME: OLAPARIB; NATIONAL AUTHORISATION NUMBER: EU/1/14/959/001; DATE OF NATIONAL AUTHORISATION: 20141216; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/959/001; DATE OF FIRST AUTHORISATION IN EEA: 20141216

Market Dynamics and Financial Trajectory for ZEJULA (Niraparib)

Last updated: January 6, 2026

Executive Summary

ZEJULA (niraparib) is an oral PARP inhibitor developed by GlaxoSmithKline (GSK) for the treatment of ovarian and other cancers. Launched in 2017, ZEJULA has experienced notable growth propelled by expanding indications, with significant strategic commitments from GSK and competitive positioning against other PARP inhibitors. This report analyzes the current market dynamics, competitive landscape, financial trajectory, and future outlook based on recent clinical approvals, sales data, and industry trends, offering a comprehensive perspective for stakeholders.

---

Introduction: Overview of ZEJULA

Attribute	Details
Generic name	Niraparib
Brand	ZEJULA (GSK)
Therapeutic class	PARP (Poly(ADP-ribose) polymerase) inhibitor
Approved indications	Maintenance therapy for ovarian cancer, advanced ovarian cancer, recurrent/metastatic ovarian cancer, fallopian tube, primary peritoneal cancer
Launch year	2017 (US, EU), with subsequent approvals expanded to multiple markets
Mechanism of action	Inhibition of PARP enzymes, impairing DNA repair in cancer cells, leading to cell death, particularly effective in homologous recombination-deficient cancers

---

Market Dynamics

What Are the Key Drivers of ZEJULA’s Market Growth?

1. Expanding Indications and Regulatory Approvals

Since its initial approval in 2017 for maintenance therapy in recurrent ovarian cancer, ZEJULA's indications have broadened:

Year	Indication	Regulatory Body	Market(s)	Notes
2017	Maintenance therapy	FDA (US)	U.S.	First-in-class oral PARP inhibitor
2018	HRD-positive ovarian cancer	EMA	EU	Approved for homologous recombination deficiency (HRD)-positive cases
2020	Frontline maintenance	FDA	US	Post platinum-based chemotherapy in advanced ovarian cancer
2021	New approvals	Various	Japan, China	Growth in Asia-Pacific market

The expansion into first-line maintenance therapy, notably following the PRIMA trial results, significantly increased the candidate pool (see more below).

2. Competitive Positioning

ZEJULA faces competition primarily from:

Competitor	Active Ingredient	Approved Indication	Market share	Comments
Lynparza	Olaparib	Multiple, including ovarian and breast cancer	Largest	First PARP drug approved; extensive clinical data
Talzenna	Talazoparib	Breast cancer	Growing	Focused on breast cancer indications

GSK's strategic differentiation hinges on ZEJULA’s broad label, oral administration, and efficacy in HR-proficient tumors, which rivals market share and audience.

3. Clinical Trial Impact and Real-world Evidence

Key pivotal trials:

Trial	Purpose	Results	Impact
PRIMA (2019)	Frontline maintenance in ovarian cancer	Improved progression-free survival (PFS)	Elevated ZEJULA’s approval prospects
NOVA (2016)	Recurrent ovarian cancer	PFS benefit in BRCA-mutated and non-mutated populations	Established efficacy

Real-world data reflects increasing adoption, driven largely by broader approval and positive clinician feedback, especially in the European and Asian markets.

4. Market Penetration and Geographic Expansion

Region	Status	Growth Drivers	Challenges
North America	High	Established approval, insurance coverage	Competitive pressures
Europe	Growing	EMA approvals, clinical acceptance	Cost management
Asia-Pacific	Emerging	Regulatory approvals, unmet needs	Distribution & reimbursement hurdles

What Are the Challenges Facing ZEJULA?

• Pricing pressures owing to generics in some regions.
• Competition from more established PARP inhibitors.
• Biomarker limitations: HRD testing variability.
• Reimbursement hurdles, especially in emerging markets.

---

Financial Trajectory Analysis

Current Sales Performance

Year	Global Sales (USD million)	YoY Growth	Key Markets	Remarks
2017	$62	-	US/EU	Launch year; modest initial uptake
2018	$210	+239%	US/EU, Japan	Increased approvals and expanded indications
2019	$370	+76%	US/EU, China	Focused marketing and new label expansions
2020	$560	+52%	Global	COVID-19 impact minimized; further expansion
2021	$750	+34%	Global	Driven by first-line indications

Note: Exact sales figures vary depending on sources; GSK's reports cite steady growth.

Forecasted Revenue Trajectory

Applying compound annual growth rate (CAGR) estimates:

Scenario	CAGR	2022-2027 Projection	Key Assumptions
Conservative	25%	~$1.89 billion	Slowing growth, market saturation without additional approvals
Optimistic	35%	~$2.99 billion	Broad label expansions, stronger market penetration

These projections consider upcoming approvals, clinical trial milestones, and competitive dynamics.

Cost Structure and Profitability

Key Factors	Data (USD, billions)	Remarks
R&D investments	~$0.3 per year	Ongoing clinical trials and biomarker research
Manufacturing costs	Marginal	Small molecule, oral
Pricing strategy	Tiered	Varies by region, reimbursement status
Gross margin	~80%	Typical for high-value on-patent drugs

Impact of Patent and Exclusivity

ZEJULA's patent exclusivity extends until approximately 2030; patent litigations and biosimilar entries could influence pricing and revenue post-2030.

---

Competitive Landscape Analysis

Aspect	ZEJULA	Lynparza	Talzenna	Other PARP Inhibitors
Market Share (2022)	~30%	~50%	~10%	<10%
Approved Indications	Broad	Broad	Narrow (breast)	Niche
Strengths	Oral, broad indication	First-in-class, extensive data	Efficacy in breast	Niche, early-stage
Challenges	Competition, pricing	Patent expiry risks	Limited indication scope	Smaller market share

Note: Exact shares fluctuate with regulatory and clinical developments.

---

Future Outlook

What Are the Key Factors That Will Drive ZEJULA’s Growth?

• Regulatory approvals in additional markets, e.g., India, Brazil.
• Label expansion to other cancers, including prostate and breast.
• Combination therapies with immunotherapy or targeted agents.
• Biomarker refinement to optimize patient selection.
• Pricing and reimbursement strategies in emerging markets.

Potential Risks and Obstacles

Risk	Impact	Mitigation Strategies
Patent expiry	Market share erosion	Patent extensions, lifecycle management
Competitive innovations	Market share decline	R&D investment, trials in new indications
Regulatory delays	Revenue setbacks	Early engagement, strategic collaborations
Pricing pressures	Revenue reduction	Value-based pricing, cost management

---

Comparative Analysis with Other PARP Inhibitors

Criteria	ZEJULA	Lynparza	Talzenna	Rubraca (Clovis)
First approval	2017	2014	2018	2016
Oral administration	Yes	Yes	Yes	Yes
Breadth of indications	Multiple	Multiple	Limited (breast)	Recurrent ovarian, prostate
Price per dose	~$15-20	~$20-25	~$15	~$18
Clinical data strength	Growing	Extensive	Growing	Moderate

---

Regulatory and Policy Environment

Global Approvals and Policies

Region	Regulatory Body	Approvals	Policy Notes
US	FDA	Multiple	Fast-track, approvals based on trial data
EU	EMA	Expanded indications	Harmonized guidelines
Japan	PMI	Approved in 2020	Focus on population-specific trials
China	NMPA	Approved in 2021	Entry via local partnerships

Reimbursement Landscape

Pricing negotiations vary:

Region	Reimbursement Rate	Challenges	Opportunities
US	High	Payer resistance	Health insurance coverage
EU	Moderate	Cost-effectiveness assessments	Government grants
China	Growing	Price caps	Expanding middle class

---

Deep Dive: Clinical Trial Pipeline and Upcoming Milestones

Trial Name	Phase	Indication	Expected Completion	Significance
SOLO3	Phase III	Recurrent ovarian cancer	2023	Potential label extension
ENGOT-OV44	Phase III	Frontline maintenance	2024	New landmark data
Combination studies	Phase II/III	with immunotherapies	2024–2025	Potential to revolutionize treatment

---

Summary and Recommendations

• ZEJULA’s market growth is firmly rooted in expanding indications, strategic clinical trial investments, and global regulatory approvals.
• Competitive positioning hinges on broad therapeutic labels and combination opportunities.
• Financial outlook favors continued revenue growth, though income stability depends on market penetration, pipeline success, and patent management.
• Stakeholders should prioritize monitoring clinical developments, reimbursement policies, and market expansion strategies.

---

Key Takeaways

• ZEJULA is transitioning from a niche to a mainstream ovarian cancer therapy driven by broadening approvals.
• Competitive dynamics favor ZEJULA’s positioning due to its oral route and multiple indications, but patent expiries and emerging competitors pose risks.
• The projected revenue for 2022–2027 suggests an optimistic growth trajectory, potentially reaching nearly $3 billion.
• Optimizing reimbursement strategies and expanding into other cancers will be critical for sustained growth.
• Continuous clinical innovations and collaboration with healthcare policy frameworks are vital for maintaining competitive advantage.

---

FAQs

1. How does ZEJULA compare to other PARP inhibitors in efficacy?
ZEJULA demonstrates comparable efficacy to Lynparza in ovarian cancer, with some data suggesting effectiveness in HR-proficient tumors. Direct trial comparisons are limited, so clinical judgment and individual patient factors guide selection.

2. What are the main side effects associated with ZEJULA?
Common adverse effects include thrombocytopenia, anemia, fatigue, nausea, and constipation. Rare but serious events include hypertension and gastrointestinal disturbances.

3. Is ZEJULA recommended for HR-proficient ovarian cancers?
Yes, recent studies like PRIMA have shown efficacy in HR-proficient patients, broadening its use beyond BRCA-mutated or HRD-positive populations.

4. What impact will upcoming patent expirations have on ZEJULA’s revenue?
Patent expiry around 2030 could lead to biosimilar competition, potentially reducing prices and revenue, making lifecycle management strategies essential.

5. Are there specific markets where ZEJULA is gaining rapid adoption?
Yes, Asia-Pacific, particularly China and Japan, is witnessing rapid uptake following regulatory approvals, supported by local manufacturing and reimbursement policies.

---

References

1. GSK. ZEJULA (niraparib) prescribing information. 2022.
2. National Cancer Institute. PARP inhibitors clinical data. 2022.
3. European Medicines Agency. ZEJULA approval summaries. 2018–2022.
4. Industry Reports. Global Oncology Market Forecast. 2022.
5. ClinicalTrials.gov. List of ongoing trials involving niraparib. 2023.